Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr. Califf Returns To US FDA: What To Do First?

Executive Summary

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

You may also be interested in...



Califf On Getting Someone Younger Than 70 To Take FDA Commissioner Job

Robert Califf says there is a reason there is such a high turnover in the top post. He notes that the continuity and dedication of center directors is one of the reasons he returned.

Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline

After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.

Califf Says Opioid Labeling Changes, Withdrawals Still Possible

The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel